Saxenda Cost in District of Columbia (2026): Prices, Insurance, and Savings

What Saxenda Costs Without Insurance

Saxenda is dispensed as a carton of pre-filled 3 mL pens at a concentration of 6 mg/mL. Without insurance, patients pay the pharmacy's cash price, which tracks close to the manufacturer's list price and typically runs into four figures per month. List prices change over time and cash prices can differ modestly between pharmacies and pharmacy benefit arrangements, so confirm the current price directly with your pharmacy or through Novo Nordisk before budgeting around a specific number.

The FDA-approved prescribing information for Saxenda sets out a five-week dose titration from 0.6 mg to the 3.0 mg maintenance dose. Because fewer pens are needed during titration, the first month of therapy can cost less than later months, and patients who tolerate only 2.4 mg will also use fewer pens.

In the pivotal SCALE Obesity and Prediabetes trial (N = 3,731), liraglutide 3.0 mg produced a mean weight loss of 8.0% of body weight at 56 weeks compared with 2.6% with placebo 1. For context, once-weekly semaglutide (Wegovy) produced 14.9% mean weight loss over a similar period in the STEP-1 trial 2. These are different molecules with different trial populations and follow-up periods, so the comparison is directional, not a guarantee of what any individual patient will experience.

Medicaid Coverage in DC

Medicaid coverage of anti-obesity medications, including Saxenda, varies by state and changes over time. A 2022 analysis of Medicaid pharmacy coverage found that only a minority of state Medicaid programs, including the District's, covered liraglutide 3 mg at that time 3. That data point is now several years old and coverage policy can change, so it should not be treated as current.

If you are a DC Medicaid enrollee, confirm current coverage, any prior-authorization requirements, and the documentation your prescriber will need (such as BMI, relevant comorbidities, and prior lifestyle-intervention history) directly with the DC Department of Health Care Finance or your Medicaid managed care plan. Clinical guidance from the American Association of Clinical Endocrinology supports pharmacotherapy as an adjunct to lifestyle intervention for patients with a BMI of 27 or higher and a weight-related complication, which is the kind of clinical documentation a prior-authorization request typically relies on, but the coverage decision itself rests with the plan, not the guideline.

Commercial Insurance in DC

Coverage for Saxenda through commercial insurance, including plans sold on DC Health Link, depends on the specific plan and carrier, its formulary tier, and its prior-authorization or step-therapy rules. Some plans exclude anti-obesity medications from coverage entirely; others cover them with conditions such as documented lifestyle intervention or a prior trial of a lower-cost agent. Out-of-pocket cost can range from a modest copay on a preferred tier to significant coinsurance on a specialty tier.

Research on barriers to obesity care has repeatedly identified insurance coverage limitations as a major obstacle to treatment access 5. Because plan design changes yearly and differs by employer and carrier, the only reliable way to know your cost is to call the number on your pharmacy benefit card and ask specifically about Saxenda's tier, any prior-authorization criteria, and your expected copay or coinsurance before filling the prescription.

Novo Nordisk Savings Card and Patient Assistance

Novo Nordisk offers a savings card for commercially insured patients that can substantially reduce the out-of-pocket cost per fill, and a separate Patient Assistance Program (PAP) for patients who meet income eligibility criteria and lack adequate coverage. Both programs exclude patients enrolled in government insurance such as Medicare, Medicaid, or Tricare from the savings card specifically.

Program terms, maximum benefit amounts, and PAP income thresholds are set by Novo Nordisk and change periodically, so confirm current eligibility and benefit amounts on Novo Nordisk's patient support site or through your prescriber rather than relying on a fixed figure. Third-party coupon services may offer additional discounts for cash-pay patients but generally cannot be combined with insurance or the manufacturer card.

Compounded Liraglutide 3 mg in DC

Compounded liraglutide 3 mg is available through licensed 503A compounding pharmacies operating under section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding of FDA-approved drugs for individual patients under a valid prescription. Compounded liraglutide is generally less expensive than brand-name Saxenda, though pricing varies by pharmacy and formulation and should be confirmed directly.

Compounded products are not FDA-approved. They have not gone through the same manufacturing quality controls, stability testing, or bioequivalence review as the brand product, and concentration or formulation can differ between compounding pharmacies and from the 6 mg/mL brand pen. Guidance from clinicians involved in obesity pharmacotherapy has generally cautioned that potency, sterility, and stability of compounded GLP-1 products may differ from the approved formulation, and that FDA-approved products are the lower-uncertainty option when cost and access allow it. If you use a compounded product, confirm your pharmacy holds current DC Board of Pharmacy licensure and that your prescriber has reviewed the specific formulation and dosing conversion with you, since dosing errors between pen and vial concentrations are a documented risk.

Telehealth Access

In DC, Saxenda can generally be prescribed through telehealth visits via national platforms and HealthRX.com. These virtual appointments typically involve reviewing your medical history, calculating BMI, and checking for contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or pregnancy 8. Because telehealth regulations and insurance coverage rules evolve, verify current DC telehealth policies with your payer rather than assuming prior information still applies.

Steps to Lower Your Out-of-Pocket Cost

1. Call your pharmacy benefit manager to confirm whether Saxenda is covered, its tier, and any prior-authorization or step-therapy requirements.
2. If commercially insured, ask your prescriber about enrolling in the Novo Nordisk savings card before your first fill.
3. If coverage is denied, ask your prescriber about an appeal with a letter of medical necessity, relevant labs, and documentation of prior lifestyle intervention; clinical guidelines supporting pharmacotherapy at your BMI and comorbidity profile can strengthen that letter.
4. If uninsured or still underinsured, ask about the Novo Nordisk Patient Assistance Program and confirm current income eligibility directly.
5. Compare cash prices across pharmacies using a coupon service if you are paying out of pocket.
6. Ask your prescriber whether compounded liraglutide through a licensed 503A pharmacy is a reasonable option if brand Saxenda remains unaffordable, understanding the tradeoffs described above.

Ongoing use, not just the first month, drives outcomes: a smaller follow-on trial reported that patients who continued liraglutide 3.0 mg after initial weight loss maintained additional weight reduction over the following year compared with placebo, though exact figures should be confirmed against the primary literature. That is worth factoring into cost planning, since a treatment that is unaffordable to continue may not deliver the outcomes seen in trials of sustained use.

Clinical Considerations

Saxenda's label includes a boxed warning regarding thyroid C-cell tumors observed in animal studies, though applicability to humans remains unclear. Nevertheless, Saxenda is contraindicated for those with personal or family history of medullary thyroid carcinoma or MEN2 8. Clinicians must assess and record thyroid history prior to initiating treatment.

Clinical guidance from endocrinology societies has supported GLP-1 receptor agonists as an effective first-line pharmacotherapy option for obesity, describing weight-loss magnitude that can approach levels previously seen mainly with bariatric surgery. In the SCALE trials, common adverse effects included nausea, diarrhea, constipation, and injection-site reactions, with nausea most common during titration and typically improving over the first several weeks 1. The FDA label recommends discontinuing Saxenda if a patient has not lost at least 4% of body weight by week 16 on the full 3.0 mg dose, since further treatment at that point is unlikely to produce clinically meaningful additional weight loss.

None of this is individualized dosing or diagnostic advice. Decisions about starting, continuing, or stopping Saxenda, and about switching to a compounded or alternative product, should be made with a prescriber who has reviewed your history.

Verification Checklist: What's Stable vs. What Changes

Some facts about Saxenda are fixed by FDA approval and clinical trial data; others depend on the current market and change without notice. Before acting on anything in this article, or anything a pharmacy or plan representative tells you, use this checklist to know which kind of fact you're dealing with.

Should any figures in this article differ from those provided by your pharmacy or insurance plan, defer to your pharmacy or plan's numbers. Saxenda pricing and coverage terms change more frequently than article updates.